



Development Support Document  
Proposed, November 2013

## **n-Butyraldehyde**

**CAS Registry Number:**  
**123-72-8**

Prepared by

Jong-Song Lee, Ph.D.

Toxicology Division

Office of the Executive Director

---

TEXAS COMMISSION ON ENVIRONMENTAL QUALITY

## TABLE OF CONTENTS

<b>LIST OF TABLES.....</b>	<b>II</b>
<b>LIST OF FIGURES.....</b>	<b>II</b>
<b>ACRONYMS AND ABBREVIATIONS.....</b>	<b>III</b>
<b>CHAPTER 1 SUMMARY TABLES AND FIGURE.....</b>	<b>1</b>
<b>CHAPTER 2 MAJOR SOURCES OR USES AND AMBIENT AIR CONCENTRATIONS.....</b>	<b>4</b>
2.1 MAJOR SOURCES OR USES .....	4
2.2 BACKGROUND LEVELS OF N-BUTYRALDEHYDE IN AMBIENT AIR.....	5
<b>CHAPTER 3 ACUTE EVALUATION.....</b>	<b>5</b>
3.1 HEALTH-BASED ACUTE REV AND ESL .....	5
3.1.1 Physical/Chemical Properties.....	5
3.1.2 Key and Supporting Studies .....	5
3.1.2.1 Key Human Study (Sim and Pattle 1957) .....	5
3.1.2.2 Supporting Animal Studies .....	6
3.1.2.2.1 Steinhagen and Barrow (1984) Study .....	6
3.1.2.2.2 USEPA (1989a) Acute Study.....	6
3.1.2.2.3 USEPA (1992a) Nine-Day Study.....	6
3.1.2.2.4 Gage (1970) Study .....	7
3.1.2.2.5 USEPA (1989b) Subacute Study .....	7
3.1.3 Reproductive/Developmental Toxicity Studies.....	8
3.1.4 Mode of Action (MOA) Analysis .....	9
3.1.5 Dose Metric.....	9
3.1.6 POD for the Key Study and Critical Effect .....	9
3.1.7 Dosimetric Adjustments .....	9
3.1.7.1 Exposure Duration Adjustments .....	9
3.1.7.2 Default Dosimetry Adjustments from Animal-to-Human Exposure .....	9
3.1.8 Adjustments of the $POD_{HEC}$ .....	10
3.1.9 Adjustments of $POD_{HEC}$ to Acute ReV and <i>acute</i> ESL.....	10
3.2 WELFARE-BASED ACUTE ESLs .....	11
3.2.1 Odor Perception.....	11
3.2.2 Vegetation Effects.....	12
3.3 SHORT-TERM ESL AND VALUES FOR AIR MONITORING DATA EVALUATIONS .....	12
3.4 ACUTE OBSERVED ADVERSE EFFECT LEVEL .....	12
<b>CHAPTER 4 CHRONIC EVALUATION.....</b>	<b>12</b>
4.1 NONCARCINOGENIC POTENTIAL .....	12
4.1.1 Physical/Chemical Properties.....	13
4.1.2 Key and Supporting Studies .....	13
4.1.2.1 Key Animal Study (USEPA 1988).....	13
4.1.2.1.1 Study I.....	13
4.1.2.1.2 Study II .....	13
4.1.3 MOA Analysis .....	14
4.1.4 Dose Metric.....	14
4.1.5 POD for Key Studies and Critical Effects .....	14
4.1.6 Dosimetric Adjustments .....	14
4.1.6.1 Exposure Duration Adjustments .....	14
4.1.6.2 Default Dosimetry Adjustments from Animal-to-Human Exposure .....	15
4.1.7 Adjustments to the $POD_{HEC}$ to Chronic ReV and <i>chronic</i> $ESL_{threshold(nc)}$ .....	15

4.1.8 Health-Based Chronic ReV and <sup>chronic</sup>ESL<sub>threshold(nc)</sub>..... 16

4.2 CARCINOGENIC POTENTIAL ..... 18

4.3 WELFARE-BASED CHRONIC ESL ..... 18

4.4 CHRONIC ESL AND VALUES FOR AIR MONITORING EVALUATION ..... 18

4.5 CHRONIC INHALATION OBSERVED ADVERSE EFFECT LEVEL..... 18

**CHAPTER 5 REFERENCES..... 19**

## LIST OF TABLES

Table 1. Air Monitoring Comparison Values (AMCVs) for Ambient Air Short-Term Values..... 1

Table 2. Air Permitting Effects Screening Levels (ESLs) ..... 2

Table 3. Chemical and Physical Data ..... 3

Table 4. Acute n-Butyraldehyde Inhalation Toxicity ..... 8

Table 5. Derivation of the Acute ReV and <sup>acute</sup>ESL ..... 11

Table 6. Derivation of the Chronic ReV and <sup>chronic</sup>ESL<sub>threshold(nc)</sub> ..... 17

## LIST OF FIGURES

**Figure 1. n-Butyraldehyde Health Effects and Regulatory Levels..... 4**

## Acronyms and Abbreviations

Acronyms and Abbreviations	Definition
AIHA	American Industrial Hygiene Association
AMCV	air monitoring comparison value
°C	degrees Celsius
DSD	development support document
ESL	effects screening level
<sup>acute</sup> ESL	acute health-based effects screening level for chemicals meeting minimum database requirements
<sup>acute</sup> ESL <sub>odor</sub>	acute odor-based effects screening level
<sup>acute</sup> ESL <sub>veg</sub>	acute vegetation-based effects screening level
<sup>chronic</sup> ESL <sub>threshold(nc)</sub>	chronic health-based effects screening level for threshold dose response noncancer effects
<sup>chronic</sup> ESL <sub>nonthreshold(c)</sub>	chronic health-based effects screening level for nonthreshold dose response cancer effects
<sup>chronic</sup> ESL <sub>veg</sub>	chronic vegetation-based effects screening level
h	hour
Hg	mercury
HEC	human equivalent concentration
HPV	high production volume
HQ	hazard quotient
IARC	International Agency for Research on Cancer
kg	kilogram
LOAEL	lowest-observed-adverse-effect-level
MW	molecular weight
µg	microgram
µg/m <sup>3</sup>	micrograms per cubic meter of air
mg	milligrams

<b>Acronyms and Abbreviations</b>	<b>Definition</b>
mg/m <sup>3</sup>	milligrams per cubic meter of air
min	minute
MOA	mode of action
n	number
NOAEL	no-observed-adverse-effect-level
POD	point of departure
POD <sub>ADJ</sub>	point of departure adjusted for exposure duration
POD <sub>HEC</sub>	point of departure adjusted for human equivalent concentration
ppb	parts per billion
ppm	parts per million
ReV	reference value
RGDR	regional gas dose ratio
TCEQ	Texas Commission on Environmental Quality
UF	uncertainty factor
UF <sub>H</sub>	interindividual or intraspecies human uncertainty factor
UF <sub>A</sub>	animal to human uncertainty factor
UF <sub>Sub</sub>	subchronic to chronic exposure uncertainty factor
UF <sub>L</sub>	LOAEL to NOAEL uncertainty factor
UF <sub>D</sub>	incomplete database uncertainty factor
USEPA	United States Environmental Protection Agency

1 **Chapter 1 Summary Tables and Figure**

2 Table 1 for air monitoring and Table 2 for air permitting provide a summary of health- and  
3 welfare-based values from an acute and chronic evaluation of n-butyraldehyde. Please refer to  
4 Section 1.6.2 of the [TCEQ Guidelines to Develop Toxicity Factors](#) (TCEQ 2012) for an  
5 explanation of air monitoring comparison values (AMCVs), reference values (ReVs) and effects  
6 screening levels (ESLs) used for review of ambient air monitoring data and air permitting. Table  
7 3 provides summary information on n-butyraldehyde’s physical/chemical data.

8 **Table 1. Air Monitoring Comparison Values (AMCVs) for Ambient Air Short-Term**  
9 **Values**


Short-Term Values	Concentration	Notes
Acute ReV [1h] (HQ = 1.0)	11,000 µg/m <sup>3</sup> (3,800 ppb) <b>Short-Term Health</b>	<b>Critical Effect(s):</b> Free-standing NOAEL due to lack of irritation or general systemic effects observed in human volunteers
<sup>acute</sup> ESL <sub>odor</sub>	4.2 µg/m <sup>3</sup> (1.4 ppb) <b>Odor</b>	Characteristic, pungent odor
<sup>acute</sup> ESL <sub>veg</sub>	---	No data found
Long-Term Values	Concentration	Notes
Chronic ReV (HQ = 1.0)	100 µg/m <sup>3</sup> (34 ppb) <b>Long-Term Health</b>	<b>Critical Effect(s):</b> Hyperplasia, inflammation, and squamous metaplasia of the nasal tissues in rats and dogs
<sup>chronic</sup> ESL <sub>nonthreshold (c)</sub>	---	Data are inadequate for an assessment of human carcinogenic potential
<sup>chronic</sup> ESL <sub>veg</sub>	---	No data found

1 **Table 2. Air Permitting Effects Screening Levels (ESLs)**

<b>Short-Term Values</b>	<b>Concentration</b>	<b>Notes</b>
<sup>acute</sup> ESL [1 h] (HQ = 0.3)	3,300 µg/m <sup>3</sup> (1,100 ppb) <sup>a</sup>	<b>Critical Effect(s):</b> Free-standing NOAEL due to lack of irritation general systemic effects observed in human volunteers
<sup>acute</sup> ESL <sub>odor</sub>	4.2 µg/m <sup>3</sup> (1.4 ppb) <b>Short-term ESL for Air Permit Reviews</b>	Characteristic, pungent odor
<sup>acute</sup> ESL <sub>veg</sub>	---	No data found
<b>Long-Term Values</b>	<b>Concentration</b>	<b>Notes</b>
<sup>chronic</sup> ESL <sub>threshold(nc)</sub> (HQ = 0.3)	30 µg/m <sup>3</sup> (10 ppb) <sup>b</sup> <b>Long-term ESL for Air Permit Reviews</b>	<b>Critical Effect(s):</b> Hyperplasia, inflammation, and squamous metaplasia of the nasal tissues in rats and dogs
<sup>chronic</sup> ESL <sub>nonthreshold(c)</sub>	---	Data are inadequate for an assessment of human carcinogenic potential
<sup>chronic</sup> ESL <sub>veg</sub>	---	No data found


2 <sup>a</sup> Based on the acute ReV of 11,000 µg/m<sup>3</sup> (3,800 ppb) multiplied by 0.3 (i.e., HQ = 0.3) to account for  
3 cumulative and aggregate risk during the air permit review.  
4 <sup>b</sup> Based on the noncarcinogenic chronic ReV of 100 µg/m<sup>3</sup> (34 ppb) multiplied by 0.3 (i.e., HQ = 0.3) to  
5 account for cumulative and aggregate risk during the air permit review.

1 **Table 3. Chemical and Physical Data**

Parameter	Value	Reference
Molecular Formula	C <sub>4</sub> H <sub>8</sub> O	ChemIDplus 2012
Chemical Structure		ChemIDplus 2012
Molecular Mass	72.1 g/mole	AIHA 2004
Physical State	Liquid	AIHA 2004
Color	Colorless	AIHA 2004
Odor	Characteristic pungent, aldehyde odor	AIHA 2004
CAS Registry Number	123-72-8	AIHA 2004
Synonyms	Butal; butaldehyde; butalyde; butanal; butanaldehyde; butyric aldehyde; butyl aldehyde; butyral	AIHA 2004
Solubility in water	7,100 mg/L @ 25°C	AIHA 2004
Log K <sub>ow</sub>	0.88	ChemIDplus 2012
Vapor Pressure	111 mm Hg @ 25°C	ChemIDplus 2012
Vapor Density (air = 1)	2.5	AIHA 2004
Density/Specific Gravity (water = 1)	0.80 @ 20°C	AIHA 2004
Melting Point	-80°C	AIHA 2004
Boiling Point	74.8°C @ 760 mm Hg	AIHA 2004
Conversion Factors	1 ppm = 2.95 mg/m <sup>3</sup> @ 25°C 1 mg/m <sup>3</sup> = 0.34 ppm	AIHA 2004

1 Figure 1 (below) compares n-butyraldehyde acute toxicity values (acute ReV, <sup>acute</sup>ESL<sub>odor</sub>, and  
2 health-based <sup>acute</sup>ESL) and chronic toxicity values (chronic ReV and long-term ESL) found in  
3 Tables 1 and 2 to the air concentrations associated with nasal irritation, and the time-weighted  
4 average (TWA) workplace environmental exposure level (WEEL) set by the American Industrial  
5 Hygiene Association (AIHA).

6 **Figure 1. n-Butyraldehyde Health Effects and Regulatory Levels**



7  
8

## 9 Chapter 2 Major Sources or Uses and Ambient Air Concentrations

### 10 2.1 Major Sources or Uses

11 n-Butyraldehyde is listed as a High Production Volume (HPV) chemical. Chemicals listed as an  
12 HPV chemical were produced in or imported into the U.S. in quantities greater than one million  
13 pounds in 1990 and/or 1994 (USEPA 2009, as cited in HSDB 2012). According to the United  
14 States Environmental Protection Agency (USEPA), “n-butyraldehyde is used as an intermediate  
15 in the production of synthetic resins, rubber accelerators, solvents, plasticizers, and high  
16 molecular weight polymers” (USEPA 1994). According to the American Industrial Hygiene

1 Association (AIHA), “n-butyraldehyde is also used as a synthetic flavoring agent in foods such  
2 as alcoholic and non-alcoholic beverages, ice cream, candy and baked goods.” It is considered  
3 “generally recognized as safe” as a food additive by the U.S. Food and Drug Administration  
4 (AIHA 2004). n-Butyraldehyde is also one of the aldehyde components of main stream cigarette  
5 smoke (Hoberman et al. 1988). The amount of n-butyraldehyde in main stream cigarette smoke  
6 ranges from 88.6-928.3 µg/cigarette (van Andel et al. 2006)

## 7 ***2.2 Background Levels of n-Butyraldehyde in Ambient Air***

8 Measurable levels of atmospheric n-butyraldehyde are associated with industrial sources. The  
9 gas-phase concentration of n-butyraldehyde in ambient Los Angeles air during photochemical  
10 pollution episodes (July-Oct 1980) ranged from 0 to 7 ppb with a median concentration of about  
11 1.5 ppb. A field monitoring study along a highway in Raleigh, North Carolina USA in May 1983  
12 detected n-butyraldehyde levels of 2.88-7.29 ppb (HSDB 2012). According to the USEPA’s fact  
13 sheet, the half-life of n-butyraldehyde in air is 16.4 hours. Its removal from air occurs primarily  
14 through reaction with photochemically-produced hydroxyl radicals (USEPA 1994). In Texas,  
15 ambient 24-h network data (carbonyl samples) showed that measured levels of n-butyraldehyde  
16 ranged from 0.01 to 0.314 ppb in Houston, El Paso, Tyler, and Dallas from 2009-2012. The  
17 highest 24-hour sample of 0.314 ppb occurred in El Paso.

## 18 **Chapter 3 Acute Evaluation**

### 19 ***3.1 Health-Based Acute ReV and ESL***

20 n-Butyraldehyde is of low acute toxicity by oral, dermal, or inhalation routes of exposure. Acute  
21 exposure to high ambient concentration can cause irritation of the eyes, nose, and throat with  
22 narcosis or anesthesia (AIHA 2004).

#### 23 **3.1.1 Physical/Chemical Properties**

24 n-Butyraldehyde is a highly flammable, colorless liquid with a characteristic pungent odor  
25 (AIHA 2004). n-Butyraldehyde is soluble in water. It has a relative high vapor pressure and is  
26 present as vapor in air. The main chemical and physical properties of n-butyraldehyde are  
27 summarized in Table 3.

#### 28 **3.1.2 Key and Supporting Studies**

29 Information regarding the acute toxicity of n-butyraldehyde in humans is limited to one study  
30 (Sim and Pattle 1957). The Sim and Pattle (1957) human study was selected as the key study to  
31 develop the acute ReV. As human data are preferred for ReV development (TCEQ 2012), other  
32 animal acute and subacute studies were used as supporting studies.

##### 33 ***3.1.2.1 Key Human Study (Sim and Pattle 1957)***

34 In a controlled inhalation study by Sim and Pattle (1957), a group of 15 healthy men aged 18 to  
35 45 years, were exposed to 230 ppm (690 mg/m<sup>3</sup>, measured concentration) n-butyraldehyde for 30

1 minutes (min). All the subjects were exposed simultaneously in a 100-m<sup>3</sup> exposure chamber.  
2 Unexposed men were used as controls. Blood pressure, pulse rates, and respiratory rates were  
3 recorded before, during, and after each exposure. Electrocardiograms were also recorded for a  
4 certain number in each group before and after exposure. No mucous membrane irritation to eye,  
5 nose, or the upper respiratory tract was observed in all exposed men. A free-standing no-  
6 observed-adverse-effect-level (NOAEL) of 230 ppm for irritation was identified from this study.  
7 The NOAEL was used as a point of departure (POD) to develop the acute ReV. 3.1.2.2  
8 Supporting Animal Studies

#### 9 **3.1.2.2.1 Steinhagen and Barrow (1984) Study**

10 Steinhagen and Barrow (1984) performed a sensory irritation study in B6C3F1 and Swiss-  
11 Webster mice. Mice were exposed to various concentrations of one of several aldehyde vapors  
12 for 10 min in a head-only exposure chamber. Sensory irritation was quantified by measuring  
13 respiratory rate depression during exposure, and five concentrations of each aldehyde were used  
14 to determine the concentration resulting in a 50% decrease in respiratory rate (RD<sub>50</sub>). The RD<sub>50</sub>  
15 values for n-butyraldehyde calculated by the authors were 1,532 ppm and 1,015 ppm for B6C3F1  
16 and Swiss-Webster mice, respectively.

#### 17 **3.1.2.2.2 USEPA (1989a) Acute Study**

18 An acute inhalation study was performed by Bio/Dynamics, Incorporated on behalf of Hoechst  
19 Celanese Corporation in 1981 and submitted to USEPA (USEPA 1989a). Five male and five  
20 female Sprague-Dawley (SD) rats were exposed to n-butyraldehyde vapor for 4 hours (h) at a  
21 target chamber concentration of 2,200 ppm (the actual mean chamber concentration was 1,820  
22 ppm). Rats were observed during the exposure and for 14 days (d) after exposure. Within 15 min  
23 of exposure, most rats had partially closed their eyes. Chromodacryorrhea (bloody tears) was  
24 observed in some rats within 30 min of exposure, and a red nasal discharge was observed in  
25 some rats after 180 min. Following exposure, all rats exhibited lacrimation (weeping eyes) and  
26 conjunctiva swelling. These symptoms were alleviated within 4 h post-exposure. Small, transient  
27 weight loss was seen in both sexes following exposure. Body weights recovered to pre-exposure  
28 values by post-exposure day 2 in most males and by post-exposure day 7 in most females. A  
29 free-standing lowest-observed-adverse-effect-level (LOAEL) of 1,820 ppm was identified from  
30 this study. Because only one dose was tested, which produced notable point of entry (POE)  
31 effects some of which were severe; the TCEQ does not consider this study to be appropriate for  
32 the development of an acute toxicity factor.

#### 33 **3.1.2.2.3 USEPA (1992a) Nine-Day Study**

34 A subacute inhalation study was performed by Carnegie-Mellon on behalf of DuPont Chemical  
35 in 1978 and submitted to the USEPA (USEPA 1992). Groups of five SD rats, five Fischer 344  
36 rats, five albino mice, three albino Guinea pigs, one rabbit, and one dog were exposed to n-  
37 butyraldehyde vapor for 6 h/d, 5 d/week for 9 d over a 2-week period at target chamber  
38 concentrations of 0, 2,000, 4,000, and 8,000 ppm (analytical average chamber concentrations  
39 were 0.05, 2,000, 3,100, and 6,400 ppm). Exposure to 6,400 ppm resulted in the death of the

1 majority of tested animals within 9 d. The principle cause of death was determined to be  
2 respiratory failure. Indications of corneal damage, including dullness and 5-10% necrosis, were  
3 observed in rabbits at 3,100 ppm. No signs of corneal injury were observed at 2,000 ppm.  
4 Decreased body weight was observed in all animals exposed to 6,400 and 3,100 ppm. The only  
5 statistically significant weight loss observed at 2,000 ppm occurred in the Fischer rats, which had  
6 developed pneumonia that was not likely associated with exposure to n-butyraldehyde, since it  
7 occurred at a similar rate in control animals. Statistically significant differences in mean liver  
8 weight values compared to the mean control values were found for the SD (both sexes) and male  
9 Fischer rats at 3,100 ppm. Definite signs of eye and respiratory irritation, and statistically  
10 significant lower body weight findings were observed in most species inhaling 6,400 and 3,100  
11 ppm of n-butyraldehyde. Only slight eye and respiratory irritation, including lacrimation,  
12 conjunctivitis, salivation, nasal discharge, and audible respiration, were observed in all animals  
13 at 2,000 ppm. A free-standing LOAEL of 2,000 ppm for body weight loss and mild sensory  
14 irritation was identified from this study.

#### 15 **3.1.2.2.4 Gage (1970) Study**

16 In a review of subacute inhalation toxicity for 109 industrial chemicals by Gage (1970), three  
17 male and four female Alderley Park specific-pathogen-free rats with an average weight of 200 g  
18 were exposed to 1,000 ppm n-butyraldehyde vapor concentration 6 h/d for 12 d. No sensory  
19 irritation or other clinical effects were observed. Histological evaluation of the lung did not find  
20 any toxic response. The level of 1,000 ppm is considered a free-standing NOAEL.

#### 21 **3.1.2.2.5 USEPA (1989b) Subacute Study**

22 An additional subacute inhalation study was performed by Bio/Dynamics Incorporated on behalf  
23 of Monsanto in 1979 and submitted to the USEPA (USEPA 1989b). One hundred SD rats (40  
24 control animals and 20 animals per dose group) equally divided by sex were exposed to n-  
25 butyraldehyde vapor for 6 h/d, 5 d/week for 4 weeks at target chamber concentrations of 0, 300,  
26 900, and 3,000 mg/m<sup>3</sup>. Actual mean chamber concentrations were 293, 930, and 2710 mg/m<sup>3</sup>,  
27 which correspond to 100, 316, and 921 ppm. Study endpoints included body weights, urinalysis,  
28 blood chemistry, hematology, and pathology. All animals survived for the duration of the study.  
29 Mean body weights did not differ between controls and all exposure groups. Male rats exposed  
30 to the highest dose of n-butyraldehyde displayed slightly depressed red blood cell counts, and  
31 slightly elevated hemoglobin values were detected in female rats exposed to the highest dose.  
32 These hematological endpoints were not considered toxicologically significant. Clinical  
33 chemistry results were within normal biological limits for all endpoints evaluated. There was a  
34 statistically significant increase in the mean adrenal/body weight ratio for male rats in the highest  
35 exposure group compared to controls. There was also a statistically significant increase in the  
36 mean lung/body weight ratio for both male and female rats in the highest exposure group  
37 compared to controls. A dose-response relationship was observed in lung/body weight ratio. The  
38 pathology report did not identify any treatment-related gross or microscopic changes in any of  
39 the exposure groups. A NOAEL of 316 ppm (930 mg/m<sup>3</sup>) was identified from this study.

1 Table 4 is a summary of acute exposure data from key and supporting studies, arranged from  
2 short duration to longer duration studies.

3 **Table 4. Acute n-Butyraldehyde Inhalation Toxicity**

<b>Exposure Concentrations (Species)</b>	<b>Exposure Time</b>	<b>NOAEL</b>	<b>LOAEL</b>	<b>End Point (Reference)</b>
230 ppm (15 healthy men)	30 min	230 ppm (Free-standing)		Absence of irritation. (Sim and Pattle 1957, Key Study)
unknown (B6C3F1 mice)	10 min	RD <sub>50</sub> = 1,015 ppm		50% decrease in respiratory rate (Steinhagen and Barrow 1984)
unknown (Swiss-Webster mice)	10 min	RD <sub>50</sub> = 1,532 ppm		50% decrease in respiratory rate (Steinhagen and Barrow 1984)
1,820 ppm (SD rats)	4 h		1,820 ppm (Free-standing)	Lacrimation and conjunctiva swelling, transient weight loss (USEPA 1989a)
0.05, 2,000, 3,100, and 6,400 ppm (SD and Fischer 344 rats)	6 h/d, 5 d/week for 9 d		2,000 ppm (Free-standing)	Body weight loss and mild sensory irritation (USEPA 1992a)
1,000 ppm (Alderley Park rats)	6 h/d for 12 d	1,000 ppm (Free-standing)		Absence of sensory irritation or other clinical effects (Gage 1970)
0, 100, 316, and 921 ppm (SD rats)	6 h/d, 5 d/week for 4 weeks	316 ppm	921 ppm	Increase in the mean lung/body weight ratio (USEPA 1989b)

4

5 **3.1.3 Reproductive/Developmental Toxicity Studies**

6 The potential reproductive and developmental inhalation toxicities of n-butyraldehyde have not  
7 been studied in humans or animals. n-Butyraldehyde is expected to be rapidly oxidized to butyric  
8 acid by aldehyde dehydrogenase and would not be expected to accumulate in humans. Following  
9 inhalation, aliphatic aldehydes (e.g., n-butyraldehyde) are known to induce mainly local effects  
10 at the site of exposure and a few systemic effects (e.g., localized lesions) probably due to little  
11 absorption through the respiratory tract (van Andel et al. 2006). There would be insignificant

1 distribution remote to the respiratory tract, so reproductive/developmental effects would be  
2 minimized at low concentrations that protect against mild sensory and respiratory effects in  
3 humans.

#### 4 **3.1.4 Mode of Action (MOA) Analysis**

5 The MOA of n-butyraldehyde for sensory irritation, which appears to be the critical effect, is  
6 unknown. However, the responses may be associated with the crosslinking of aldehydes with  
7 proteins (Steinhagen and Barrow 1984). Because the hydrated form of an aldehyde may be  
8 responsible for protein crosslinking, the relative potency of an aldehyde may be related to the  
9 degree to which it hydrates. In addition, the MOA is similar to that for formaldehyde (TCEQ  
10 2008) and thus, the MOA for minor eye or sensory irritation after exposure to n-butyraldehyde  
11 may involve interaction with local nerve endings or trigeminal stimulation.

#### 12 **3.1.5 Dose Metric**

13 Since the key study is based on human volunteers exposed to the parent chemical, exposure  
14 concentration of the parent chemical will be used as the default dose metric.

#### 15 **3.1.6 POD for the Key Study and Critical Effect**

16 The 30-min free-standing NOAEL of 230 ppm for absence of sensory irritation observed in the  
17 Sim and Pattle (1957) human inhalation study was used as the POD to derive the acute ReV for  
18 n-butyraldehyde. Eye and respiratory irritation was observed in several acute and subacute  
19 animal studies. The sensory irritation observed in animals is assumed similar to humans.  
20 Additionally, irritation of mucous surfaces was reported in healthy men exposed to other  
21 aldehydes, i.e., formaldehyde, acetaldehyde, and crotonaldehyde (Sim and Pattle 1957). Thus,  
22 upper respiratory tract irritation is considered the critical effect for acute n-butyraldehyde  
23 exposures.

#### 24 **3.1.7 Dosimetric Adjustments**

##### 25 ***3.1.7.1 Exposure Duration Adjustments***

26 The POD from the Sim and Pattle (1957) human inhalation study is based on a free-standing  
27 NOAEL of 230 ppm for irritation. Since eye or respiratory irritation is a concentration-dependent  
28 effect, a duration adjustment from 30-min to 1 h was not applied. Therefore, the 30-min  $POD_{HEC}$   
29 applicable for a 1-h exposure is 230 ppm.

##### 30 ***3.1.7.2 Default Dosimetry Adjustments from Animal-to-Human Exposure***

31 Since the  $POD_{ADJ}$  is based on human volunteer exposure, the  $POD_{ADJ}$  of 230 ppm was directly  
32 used as a human equivalent concentration ( $POD_{HEC}$ ) to set the acute ReV.

### 1 **3.1.8 Adjustments of the $POD_{HEC}$**

2 The MOA by which n-butyraldehyde produces irritation is assumed to have a threshold for the  
3 response, so a POD was determined and uncertainty factors (UFs) were applied to derive an  
4 acute ReV. The following UFs were applied to the  $POD_{HEC}$  of 230 ppm:

- 5 • a full  $UF_H$  of 10 was used to account for intraspecies variability;
- 6 • a  $UF_D$  of 6 was used because the acute database for n-butyraldehyde includes only one  
7 acute inhalation study in humans (key study); one acute and three subacute animal  
8 inhalation exposure supporting studies in multiple species. Among these studies, only one  
9 study (USEPA 1989b) showed a dose-response relationship in body/organ weight loss.  
10 There are no reproductive/developmental toxicity studies although significant systemic  
11 absorption is not expected. The quality of the database and key study are considered  
12 medium; and the confidence in the acute database is medium; and thus
- 13 • the total UF = 60.

$$\begin{aligned} 14 \text{ Acute ReV} &= POD_{HEC} / (UF_H \times UF_D) \\ 15 &= 230 \text{ ppm} / (10 \times 6) \\ 16 &= 3.833 \text{ ppm} \\ 17 &= 3,800 \text{ ppb} (11,000 \mu\text{g}/\text{m}^3) \end{aligned}$$

### 18 **3.1.9 Adjustments of $POD_{HEC}$ to Acute ReV and <sup>acute</sup>ESL**

19 In deriving the acute ReV, no numbers were rounded between equations until the ReV was  
20 calculated. Once the ReV was calculated, it was rounded to two significant figures. The rounded  
21 ReV of 3,800 ppb ( $11,000 \mu\text{g}/\text{m}^3$ ) was then used to calculate the ESL. The <sup>acute</sup>ESL of 1,100 ppb  
22 ( $3,300 \mu\text{g}/\text{m}^3$ ) is based on the acute ReV multiplied by a hazard quotient (HQ) of 0.3, then  
23 rounded to two significant figures at the end of all calculations (Table 5).

1 **Table 5. Derivation of the Acute ReV and <sup>acute</sup>ESL**

Parameter	Summary
Study	Sim and Pattle (1957)
Study Population	Fifteen male volunteers (aged 18-45)
Study Quality	Medium
Exposure Method	Inhalation of 230 ppm (measured concentration) exposure
Exposure Duration	30 min
Critical Effects	Absence of sensory irritation in human volunteers
NOAEL	230 ppm (Free-standing NOAEL)
POD	230 ppm
Extrapolation to 1 h (POD <sub>ADJ</sub> )	230 ppm (no adjustment – effects were concentration dependent)
POD <sub>HEC</sub>	230 ppm
Total uncertainty factors (UFs)	60
<i>Interspecies UF</i>	N/A
<i>Intraspecies UF</i>	10
<i>LOAEL-to-NOAEL UF</i>	N/A
<i>Incomplete Database UF</i>	6
<i>Database Quality</i>	Medium
Acute ReV [1 h] (HQ = 1)	<b>11,000 µg/m<sup>3</sup> (3,800 ppb)</b>
<sup>acute</sup> ESL [1 h] (HQ = 0.3)	<b>3,300 µg/m<sup>3</sup> (1,100 ppb)</b>

2

3 **3.2 Welfare-Based Acute ESLs**

4 **3.2.1 Odor Perception**

5 n-Butraldehyde has a characteristic pungent odor. An odor detection threshold of 4.6, 3.1, and  
6 0.67 ppb were reported by Hellman (1973, 1974), van Doorn (2002), and Nagata (2003),  
7 respectively. These odor detection values meet the criteria accepted by the American Industrial  
8 Hygiene Association (AIHA) and the USEPA (AIHA 1989 and USEPA 1992b). According to  
9 the TCEQ Guidelines for setting odor-based ESLs (TCEQ 2012), odor detection values defined

1 as the highest quality level of odor thresholds (Level 1) will be considered first in setting the  
2 <sup>acute</sup>ESL<sub>odor</sub> values. The odor detection thresholds reported by van Doorn (2002) and Nagata  
3 (2003) were determined by the standardized methods of measuring odor and are defined as Level  
4 1 quality data. The odor threshold reported by Hellman (1973, 1974), however, is defined as  
5 Level 3 quality data. Therefore, only the standardized odor detection thresholds determined by  
6 van Doorn (2002) and Nagata (2003) were used to set the <sup>acute</sup>ESL<sub>odor</sub>. Because more than one  
7 Level 1 study was located, the geometric mean of the 50% odor detection thresholds from these  
8 studies was calculated. Accordingly, the <sup>acute</sup>ESL<sub>odor</sub> for n-butyraldehyde 1.4 ppb (4.2 µg/m<sup>3</sup>).  
9 Because odor is a concentration-dependent effect, the same 1-h <sup>acute</sup>ESL<sub>odor</sub> can be assigned to all  
10 averaging times for monitoring and modeling samples.

### 11 **3.2.2 Vegetation Effects**

12 After careful review of the current literature, no information regarding the vegetative toxicity of  
13 n-butyraldehyde was found.

### 14 **3.3 Short-Term ESL and Values for Air Monitoring Data Evaluations**

15 The acute evaluation resulted in the derivation of the following values for n-butyraldehyde:

- 16 • Acute ReV = 11,000 µg/m<sup>3</sup> (3,800 ppb )
- 17 • <sup>acute</sup>ESL = 3,300 µg/m<sup>3</sup> (1,100 ppb )
- 18 • <sup>acute</sup>ESL<sub>odor</sub> = 4.2 µg/m<sup>3</sup> (1.4 ppb)

19 For the evaluation of ambient air monitoring data, both the acute ReV of 11,000 µg/m<sup>3</sup> (3,800  
20 ppb) and <sup>acute</sup>ESL<sub>odor</sub> of 4.2 µg/m<sup>3</sup> (1.4 ppb) are used (Table 1). The short-term ESL for air permit  
21 reviews is the <sup>acute</sup>ESL<sub>odor</sub> of 4.2 µg/m<sup>3</sup> (1.4 ppb) as it is lower than the health-based <sup>acute</sup>ESL of  
22 3,300 µg/m<sup>3</sup> (1,100 ppb) (Table 2).

### 23 **3.4 Acute Observed Adverse Effect Level**

24 The acute POD from the key study is a free-standing acute NOAEL of 230 ppm in human  
25 volunteers. The lowest acute LOAEL is 1,820 ppm for lacrimation and conjunctiva swelling,  
26 transient weight loss in rats (USEPA 1989a). However, only one dose (1,820 ppm) was  
27 conducted in this study and the free-standing LOAEL is much higher than the NOAEL of 230  
28 ppm in humans. Thus, the acute observed adverse effect level was not calculated.

## 29 **Chapter 4 Chronic Evaluation**

### 30 **4.1 Noncarcinogenic Potential**

31 No animal studies or reports of adverse human effects from chronic exposure to n-butyraldehyde  
32 were found. The effect of most probable concern from chronic low level exposure is respiratory  
33 tract irritation as evidenced by increased lung weights in the subacute as well as subchronic

1 inhalation studies (USEPA 1988, 1989a,b). Subchronic inhalation studies in laboratory animals  
2 have demonstrated mortality and localized lesions in response to irritation as well as some effects  
3 on hematology and clinical chemistry (USEPA 1994).

#### 4 **4.1.1 Physical/Chemical Properties**

5 For physical/chemical properties, refer to Section 3.1 and Table 3.

#### 6 **4.1.2 Key and Supporting Studies**

7 A series of studies on the subchronic inhalation toxicity of n-butyraldehyde conducted by Union  
8 Carbide Corporation in 1979 (unpublished) and submitted to the USEPA in 1988 (USEPA 1988)  
9 was selected as the key study for the derivation of chronic toxicity factors. No other subchronic  
10 studies were available for supporting studies.

##### 11 **4.1.2.1 Key Animal Study (USEPA 1988)**

###### 12 **4.1.2.1.1 Study I**

13 In the Union Carbide Corporation 1979 studies (USEPA 1988), groups of male and female SD  
14 rats (20 rats/sex/group) and four male beagle dogs per group were exposed to n-butyraldehyde  
15 vapor at target concentrations of 0, 125, 500, or 2,000 ppm (mean measured concentrations of 0,  
16 117, 482, or 1852 ppm) for 6 h/d, 5 d/week, for 13 and 14 weeks, respectively. There was a full  
17 investigation with respect to body and organ weights, urinalysis, blood chemistry, pathology and  
18 hematological examinations. Clinical signs of ocular and upper respiratory tract irritation occurred at  
19 all exposure groups. Histopathologic changes in rats displayed a significant increase in the  
20 incidence of squamous metaplasia of the nasal cavity in all treatment groups. The incidence and  
21 severity generally decreased with decreasing exposure concentration. Dogs exposed to 117 and  
22 482 ppm displayed goblet cell hyperplasia within the nasal mucosa; dogs in the 1852 ppm  
23 treatment group displayed hyperplasia, inflammation, and squamous metaplasia of the nasal  
24 tissues. The changes are indicative of a response to repeated upper respiratory tract irritation. No  
25 other treatment-related effects (i.e., systemic effects) on body weight, serum chemistry,  
26 hematology, urinalysis, or liver or kidney weights for rats or dogs between exposure and control  
27 groups were noted. No other exposure-related lesions were observed in rats or dogs. Therefore, a  
28 free-standing LOAEL of 117 ppm in both rats and dogs for hyperplasia, inflammation, and  
29 squamous metaplasia of nasal mucosa, was identified from these studies.

###### 30 **4.1.2.1.2 Study II**

31 In a subsequent inhalation study to evaluate a no-effect level for squamous metaplasia of the  
32 nasal mucosa, 15 Fischer-344 rats per sex per group were exposed to mean measured  
33 concentrations of 0, 1.1, 10.3, and 51.3 ppm n-butyraldehyde, 6 h/d, 5 d/week for 12 weeks.  
34 Evaluation for toxic effects included body weight, food consumption, organ weight, serum  
35 chemistry, histopathologic changes, ophthalmologic and neurologic examinations. No treatment-  
36 related effects were observed in any exposure group. Histopathologic findings indicated that no  
37 specific adverse effects including squamous metaplasia of the nasal, olfactory, or respiratory

1 epithelial tissues could be attributed to n-butyraldehyde. A NOAEL of 51.3 ppm for irritation of  
2 respiratory tract was therefore identified from this study. The subchronic NOAEL was then used  
3 as the POD to derive the chronic ReV.

#### 4 **4.1.3 MOA Analysis**

5 As described in Section 3.3, the MOA for irritation, which appears to be the critical effect, is  
6 unknown. However, the responses may be associated with the crosslinking of aldehydes with  
7 proteins (Steinhagen and Barrow 1984). Because the hydrated form of an aldehyde may be  
8 responsible for protein crosslinking, the relative potency of an aldehyde may be related to the  
9 degree to which it hydrates.

#### 10 **4.1.4 Dose Metric**

11 Since the key study is based on animals exposed to the parent chemical, exposure concentration  
12 of the parent chemical is the default dose metric.

#### 13 **4.1.5 POD for Key Studies and Critical Effects**

14 The NOAEL of 51.3 ppm for hyperplasia, inflammation, and squamous metaplasia of nasal  
15 mucosa identified from the Union Carbide (1979) 12-week inhalation study in rats (USEPA  
16 1988) was used as the POD to derive the chronic ReV for n-butyraldehyde. The critical effects  
17 noted in rats were considered relevant to humans, although humans may be less susceptible to  
18 the degeneration of nasal and olfactory epithelium because rats are obligate nose-breathers and  
19 the delivered dose to the nasal and olfactory epithelium is higher in rats than humans. However,  
20 the associated LOAEL for hyperplasia, inflammation, and squamous metaplasia of nasal mucosa  
21 from Study I also occurred in dogs, in addition to rats.

#### 22 **4.1.6 Dosimetric Adjustments**

##### 23 ***4.1.6.1 Exposure Duration Adjustments***

24 According to the TCEQ (2012), the subchronic POD of 51.3 ppm was then adjusted from  
25 discontinuous exposure (6 h/d for 5d/week) to continuous exposure concentration using the  
26 following dosimetric adjustments:

$$27 \quad \text{POD}_{\text{ADJ}} = \text{POD} \times \text{D} / 24 \times \text{F}/7$$

$$28 \quad \text{POD}_{\text{ADJ}} = 51.3 \text{ ppm} \times 6/24 \times 5/7$$

$$29 \quad \text{POD}_{\text{ADJ}} = 9.16 \text{ ppm}$$

30 where:

31  $\text{POD}_{\text{ADJ}}$  = POD from an animal study, adjusted to a continuous exposure duration

32 POD = POD from an animal study, based on a discontinuous exposure duration

33 D = exposure duration, h/d

34 F = exposure frequency, d/week

#### 4.1.6.2 Default Dosimetry Adjustments from Animal-to-Human Exposure

Subchronic exposures to n-butyraldehyde caused hyperplasia, inflammation, and squamous metaplasia of the nasal tissues, which is considered contact site toxicity or a POE effect, so default dosimetric adjustments from animal-to-human exposure for n-butyraldehyde were conducted as a Category 1 vapor. When the critical effect is in the extrathoracic region (ET) region, the animal-to-human dosimetric adjustments will use a default DAF of 1, as recommended by the USEPA 2012 Advances in Inhalation Gas Dosimetry summary document (USEPA 2012). Accordingly, the default dosimetric adjustment from animal-to-human exposure is conducted using the following equation:

$$POD_{HEC} = POD_{ADJ} \times \text{default DAF}$$

$$= 9.16 \text{ ppm} \times 1$$

$$= 9.16 \text{ ppm}$$

#### 4.1.7 Adjustments to the $POD_{HEC}$ to Chronic ReV and $^{chronic}ESL_{\text{threshold(nc)}}$

The MOA by which n-butyraldehyde produces hyperplasia, inflammation, and squamous metaplasia of nasal mucosa is assumed to produce a threshold for response, so a  $POD_{HEC}$  was determined and UFs were applied to derive the chronic ReV. The following UFs were applied to the  $POD_{HEC}$ :

- $UF_H = 10$  was used to account for human variation;
- $UF_A = 3$  was used for extrapolation from animals to humans because default dosimetric adjustments from animal-to-human exposure were conducted, which account for toxicokinetic differences but not toxicodynamic differences;
- $UF_{Sub} = 3$  because the rat exposure durations in the Union Carbide study were 12 and 13 weeks (i.e.  $\leq 13$  weeks), which is considered a subchronic exposure duration for rats (USEPA 1994) for Study II and Study I, respectively. Additionally, as indicated in Section 3.1.6, n-butyraldehyde which has low  $K_{ow}$  is expected to be rapidly oxidized to butyric acid by aldehyde dehydrogenase and is not expected to accumulate in humans. Thus, a  $UF_{Sub}$  of 3 is considered sufficient;
- $UF_D = 3$  because the noncancer database relevant to long-term exposure includes only one subchronic animal inhalation study, although multiple doses and two species (rats and dogs) were studied. No other studies are available for supporting studies. The quality of the key study is considered high; however, the confidence in the database is low to medium and thus.
- The total  $UF = 270$ .

1 **4.1.8 Health-Based Chronic ReV and <sup>chronic</sup>ESL<sub>threshold(nc)</sub>**

2 The chronic ReV value was calculated by the following equation:

3           Chronic ReV =  $POD_{HEC} / (UF_H \times UF_A \times UF_{Sub} \times UF_D)$   
4                           =  $POD_{HEC} / (10 \times 3 \times 3 \times 3)$   
5                           = 9.16 ppm / 270  
6                           = 9,160 ppb / 270  
7                           = 33.93 ppb (100.09  $\mu\text{g}/\text{m}^3$ )

8 The chronic ReV values were rounded to two significant figures at the end of all calculations.

9 The derived chronic ReV of 34 ppb ( $100 \mu\text{g}/\text{m}^3$ ) was used to calculate the <sup>chronic</sup>ESL<sub>threshold(nc)</sub>.

10 The <sup>chronic</sup>ESL<sub>threshold(nc)</sub> of 10 ppb ( $30 \mu\text{g}/\text{m}^3$ ) is based on the chronic ReV multiplied by a HQ of  
11 0.3, then rounded to two significant figures at the end of all calculations (Table 6 below). The  
12 resulting ReV and <sup>chronic</sup>ESL<sub>threshold(nc)</sub> are used for the evaluation of ambient air monitoring data  
13 and air permits.

1 **Table 6. Derivation of the Chronic ReV and <sup>chronic</sup>ESL<sub>threshold(nc)</sub>**

<b>Parameter</b>	<b>Summary</b>
Study	Union Carbide study (USEPA 1988)
Study Population	15 Fischer-344 rats per sex per group; SD rats (20 rats/sex/group); and 4 male beagle dogs per group
Study Quality	High
Exposure Method	Via inhalation at 0, 1.1, 10.3, and 51.3 ppm (analytical concentrations) for Fischer-344 rats (Study II); and 0, 117, 482, or 1852 ppm (analytical concentrations) for SD rats and male beagle dogs (Study I)
Critical Effects	Hyperplasia, inflammation, and squamous metaplasia of the nasal tissues (nasal irritation) in SD rats and male beagle dogs
LOAEL	117 ppm in SD rats and beagle dogs (Study I, free-standing LOAEL from Study I)
NOAEL	51.3 ppm in Fischer-344 rats (Free-standing NOAEL from Study II)
POD (original animal study)	51.3 ppm
Exposure Duration	6 h/d, 5 d/week, for 13-14 weeks (Study I) and 12 weeks (Study II)
Extrapolation to continuous exposure (POD <sub>ADJ</sub> )	9.16 ppm
POD <sub>HEC</sub>	9.16 ppm
Total UFs	270
<i>Interspecies UF</i>	3
<i>Intraspecies UF</i>	10
<i>LOAEL UF</i>	Not applicable
<i>Sub chronic to chronic UF</i>	3
<i>Incomplete Database UF</i>	3
<i>Database Quality</i>	Low to medium
<b>Chronic ReV (HQ = 1)</b>	<b>100 µg/m<sup>3</sup> (34 ppb)</b>
<b><sup>chronic</sup>ESL<sub>threshold(nc)</sub> (HQ = 0.3)</b>	<b>30 µg/m<sup>3</sup> (10 ppb)</b>

## 4.2 Carcinogenic Potential

No carcinogenicity study for n-butyraldehyde is available. Evidence for the potential carcinogenicity of n-butyraldehyde is inconclusive (NIOSH 1991, USEPA 1994). Results from short term mutagenicity testing of n-butyraldehyde are mixed. n-Butyraldehyde was negative for mutation in five strains of *Salmonella typhimurium* with or without metabolic activation up to 10 mg/plate (HSDB 2012). n-Butyraldehyde was negative for sister chromatid exchange in human lymphocytes but positive in Chinese hamster ovary cells (<9 mg/mL). The chemical was negative for sex-linked recessive lethal in *Drosophila melanogaster* (Dynamac Corporation 1988, as cited in USEPA 1994). Moutschen-Dahmen et al. (1976, as cited in NIOSH 1991) reported that n-butyraldehyde induces chromosomal damage and meiotic anomalies in male mice during spermatogenesis in both gavage and inhalation studies. n-Butyraldehyde is not included in International Agency for Research on Cancer (IARC) animal or human carcinogenic classification. USEPA (1994) concludes there is insufficient evidence in either humans or animals to classify n-butyraldehyde as to its potential carcinogenicity.

## 4.3 Welfare-Based Chronic ESL

No information was found to indicate that chronic vegetation effects result from exposure to n-butyraldehyde.

## 4.4 Chronic ESL and Values for Air Monitoring Evaluation

The chronic evaluation resulted in the derivation of the following values:

- Chronic ReV = 100  $\mu\text{g}/\text{m}^3$  (34 ppb)
- $^{\text{chronic}}\text{ESL}_{\text{threshold(nc)}} = 30 \mu\text{g}/\text{m}^3$  (10 ppb)

The long-term ESL for air permit evaluations is the  $^{\text{chronic}}\text{ESL}_{\text{threshold(nc)}}$  of 30  $\mu\text{g}/\text{m}^3$  (10 ppb) as no  $^{\text{chronic}}\text{ESL}_{\text{nonthreshold(c)}}$  was derived (Table 2). The  $^{\text{chronic}}\text{ESL}_{\text{threshold(nc)}}$  is set to protect noncancer nasal lesions from chronic exposure. For evaluation of air monitoring data, the chronic ReV of 100  $\mu\text{g}/\text{m}^3$  (34 ppb) is used (Table 1). The  $^{\text{chronic}}\text{ESL}_{\text{threshold(nc)}}$  (HQ = 0.3) is not used to evaluate ambient air monitoring data.

## 4.5 Chronic Inhalation Observed Adverse Effect Level

The free-standing subchronic LOAEL of 117 ppm from the Union Carbide Study I (USEPA 1988) that evaluated upper respiratory tract irritation in SD rats and beagle dogs (Tables 5) was used as the initial POD for calculation of a chronic inhalation LOAEL. No duration adjustment was made (TCEQ 2012). However, an animal-to-human dosimetric adjustment was made to the  $\text{LOAEL}_{\text{ADJ}}$  to calculate a  $\text{LOAEL}_{\text{HEC}}$ . As indicated in Section 4.1.6.2, the critical effect (hyperplasia, inflammation, and squamous metaplasia of the nasal tissues) is considered contact site toxicity or a POE effect, so default dosimetric adjustments from animal-to-human exposure for n-butyraldehyde were conducted as a Category 1 vapor. Since, the critical effect is in the extrathoracic region (ET) region, the animal to human dosimetric adjustments will use a default DAF of 1. Accordingly, the  $\text{LOAEL}_{\text{HEC}}$  was calculated using the following equation:

$$\begin{aligned} \text{LOAE}_{\text{HEC}} &= \text{LOAE}_{\text{ADJ}} \times \text{default DAF} \\ &= 117 \text{ ppm} \times 1 \\ &= 120 \text{ ppm (rounded to two significant figures)} \end{aligned}$$

The  $\text{LOAE}_{\text{HEC}}$  determined from animal studies, where effects occurred in animals, represents a concentration at which it is possible that similar effects could occur in some individuals exposed to this level over the same duration as used in the study or longer. Importantly, effects are not a certainty due to potential interspecies and intraspecies differences in sensitivity. The chronic inhalation observed adverse effect level of 120 ppm is provided for informational purposes only (TCEQ 2012).

The margin of exposure between the chronic inhalation observed adverse effect level of 120 ppm (120,000 ppb) to the chronic ReV of 34 ppb is a factor of 3500.

## Chapter 5 References

- American Industrial Hygiene Association (AIHA). 2004. Workplace Environmental Exposure Level for Butyraldehyde. AIHA, Fairfax, VA.
- American Industrial Hygiene Association (AIHA). 1989. Odor Thresholds for Chemical with Established Occupational Health Standards. Akron, OH.
- ChemIDplus Lite. 2012. Physical Properties for Butyraldehyde (CAS No. 123-72-8). U.S. National Library of Medicine. Available from: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?CHEM>
- Dalham T, A Rosengren. 1971. Effect of different aldehydes on tracheal mucosa. Arch Otolaryng 93:496-500.
- Dillon D, R Combes, E Zeiger. 1998. The effectiveness of *Salmonella* strains TA100, TA102 and TA104 for detecting mutagenicity of some aldehydes and peroxides. Mutagenesis 13(1): 19-26.
- Gage JC. 1970. The subacute inhalation toxicity of 109 industrial chemicals. Brit J Industr Med. 27: 1-18. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1009036/pdf/brjindmed00105-0007.pdf>
- Hazardous Substance Databank (HSDB). 2012. Health and environmental database available via ToxNet of the National Library of Medicine, Bethesda, MD. Available from: <http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~Fd67qn:1>
- Nagata, Y. 2003. Measurement of odor threshold by triangle odor bag method. Odor Measurement Review, Japan Ministry of the Environment. Pp. 118-127. Available from: [http://www.env.go.jp/en/air/odor/measure/02\\_3\\_2.pdf](http://www.env.go.jp/en/air/odor/measure/02_3_2.pdf)

- 1 National Institute for Occupational Safety and Health (NIOSH). 1991. Current Intelligence  
2 Bulletin No.55 - Carcinogenicity of acetaldehyde and malonaldehyde, and mutagenicity  
3 of related low-molecular-weight aldehydes. Cincinnati, OH. 39p, Available from:  
4 <http://www.cdc.gov/niosh/docs/91-112/>
- 5 Sim VM, RE Pattle. 1957. Effect of possible smog irritants on human subjects. J Am Med Asso.  
6 163(13): 1908-1913.
- 7 Steinhagen W, C Barrow. 1984. Sensory irritation structure-activity study of inhaled aldehydes  
8 in B6C3F<sub>1</sub> and Swiss-Webster Mice. Toxicol Appl Pharmacol. 72(3):495-503.
- 9 Texas Commission on Environmental Quality (TCEQ). 2008. Development support document  
10 Formaldehyde, CAS registry numbers: 50-00-0. Texas Commission on Environmental  
11 Quality, Toxicology Division, Chief Engineer's Office, available at  
12 <http://www.tceq.state.tx.us/implementation/tox/dsd/final.html>
- 13 Texas Commission on Environmental Quality (TCEQ). 2012. TCEQ Guidelines to Develop  
14 Toxicity Factors. RG-442. Office of Executive Director. Available from:  
15 <http://www.tceq.texas.gov/publications/rg/rg-442.html>
- 16 United States Environmental Protection Agency (USEPA). 1988. Butyraldehyde Vapor  
17 Inhalation by Dogs and Rats for 14 and 23 Weeks Respectively and a 12 Week Vapor  
18 Inhalation Study in Rats with Attached Appendices and Cover Letter dated 02/22/88.  
19 USEPA Office of Toxic Substances FYI-OTS-1088-0647D (NTIS/OTS-0000647):102
- 20 United States Environmental Protection Agency (USEPA). 1989a. Acute toxicity, primary & eye  
21 irritation studies in rabbits, a dermal sensitization study in guinea pigs & an acute  
22 inhalation toxicity study of C-243 in rat w-attachments & letter. Dated 1/27/89.  
23 EPA/OTS 0516658.
- 24 United States Environmental Protection Agency (USEPA). 1989b. Health Effects Assessment for  
25 Butyraldehyde at the Nitro Plant (final Report) with Attachment and Cover Letter. Dated  
26 12/28/89. EPA/OTS 0521603.
- 27 United States Environmental Protection Agency (USEPA). 1992a. Butyraldehyde: 9-day  
28 repeated vapor inhalation toxicity, vapor inhalation by dogs and rats for 12 and 13 weeks,  
29 respectively and a 12-week vapor inhalation study in rats with letter 020689. EPA /OTS:  
30 Doc #86 890000097, Washington, D.C.
- 31 United States Environmental Protection Agency (USEPA). 1992b. Reference guide to odor  
32 threshold for hazardous air pollutants listed in the Clean Air Act Amendments of 1990.  
33 EPA600/R-92/047. Office of Research and Development, Washington, DC.

- 1 United States Environmental Protection Agency (USEPA). 1994. Pollution Prevention and  
2 Toxics. OPPT Chemical Fact Sheets. Butyraldehyde Fact Sheet: Support Document  
3 (CAS No. 123-72-8). EPA 749-F-95-005a, Washington, D.C. Available from:  
4 <http://www.epa.gov/chemfact/butyr-sd.txt>
- 5 United States Environmental Protection Agency (USEPA). 2012. Advances in Inhalation Gas  
6 Dosimetry for Derivation of a Reference Concentration (RfC) and Use in Risk  
7 Assessment. EPA/600/R-12/044, Washington, D.C. Available from:  
8 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=244650#Download>
- 9 van Andel, I, A Sleijffers, E Schenk, et al. 2006. Adverse health effects of cigarette smoke:  
10 aldehydes, Crotonaldehyde, butyraldehyde, hexanal, and malonaldehyde. RIVM report  
11 340630002/2006. Bilthoven, Netherland. Available from:  
12 <http://www.rivm.nl/bibliotheek/rapporten/340630002.pdf>
- 13 van Doorn, R, MW Ruijten, and T Van Harreveld. 2002. Guidance for the Application of Odor  
14 in Chemical Emergency Response. Version 2.1; August 29, 2002. Presented at the  
15 NAC/AEGL-Meeting September 2002, Washington DC.